153 related articles for article (PubMed ID: 26225945)
1. Cost-Effectiveness of High-Risk Human Papillomavirus Testing With Messenger RNA Versus DNA Under United States Guidelines for Cervical Cancer Screening.
Ting J; Smith JS; Myers ER
J Low Genit Tract Dis; 2015 Oct; 19(4):333-9. PubMed ID: 26225945
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance.
Kim JJ; Wright TC; Goldie SJ
JAMA; 2002 May; 287(18):2382-90. PubMed ID: 11988059
[TBL] [Abstract][Full Text] [Related]
3. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.
Arbyn M; Ronco G; Anttila A; Meijer CJ; Poljak M; Ogilvie G; Koliopoulos G; Naucler P; Sankaranarayanan R; Peto J
Vaccine; 2012 Nov; 30 Suppl 5():F88-99. PubMed ID: 23199969
[TBL] [Abstract][Full Text] [Related]
4. Sensitivity, specificity, and clinical value of human papillomavirus (HPV) E6/E7 mRNA assay as a triage test for cervical cytology and HPV DNA test.
Benevolo M; Vocaturo A; Caraceni D; French D; Rosini S; Zappacosta R; Terrenato I; Ciccocioppo L; Frega A; Giorgi Rossi P
J Clin Microbiol; 2011 Jul; 49(7):2643-50. PubMed ID: 21525231
[TBL] [Abstract][Full Text] [Related]
5. Primary hrHPV DNA testing in cervical cancer screening: how to manage screen-positive women? A POBASCAM trial substudy.
Dijkstra MG; van Niekerk D; Rijkaart DC; van Kemenade FJ; Heideman DA; Snijders PJ; Meijer CJ; Berkhof J
Cancer Epidemiol Biomarkers Prev; 2014 Jan; 23(1):55-63. PubMed ID: 23733907
[TBL] [Abstract][Full Text] [Related]
6. Screening for Cervical Cancer in Primary Care: A Decision Analysis for the US Preventive Services Task Force.
Kim JJ; Burger EA; Regan C; Sy S
JAMA; 2018 Aug; 320(7):706-714. PubMed ID: 30140882
[TBL] [Abstract][Full Text] [Related]
7. Estimated Quality of Life and Economic Outcomes Associated With 12 Cervical Cancer Screening Strategies: A Cost-effectiveness Analysis.
Sawaya GF; Sanstead E; Alarid-Escudero F; Smith-McCune K; Gregorich SE; Silverberg MJ; Leyden W; Huchko MJ; Kuppermann M; Kulasingam S
JAMA Intern Med; 2019 Jul; 179(7):867-878. PubMed ID: 31081851
[TBL] [Abstract][Full Text] [Related]
8. The reliability of high-risk human papillomavirus detection by Aptima HPV assay in women with ASC-US cytology.
Castle PE; Reid J; Dockter J; Getman D
J Clin Virol; 2015 Aug; 69():52-5. PubMed ID: 26209379
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic validity of human papillomavirus E6/E7 mRNA test in cervical cytological samples.
Liu TY; Xie R; Luo L; Reilly KH; He C; Lin YZ; Chen G; Zheng XW; Zhang LL; Wang HB
J Virol Methods; 2014 Feb; 196():120-5. PubMed ID: 24216236
[TBL] [Abstract][Full Text] [Related]
10. Accuracy of Messenger RNA Human Papillomavirus Tests for Diagnostic Triage of Minor Cytological Cervical Lesions: A Systematic Review and Meta-Analysis.
Macedo ACL; Bavaresco DV; Gonçalves JCN; Grande AJ; da Rosa MI
Sex Transm Dis; 2019 May; 46(5):297-303. PubMed ID: 30985633
[TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness of human papillomavirus testing to augment cervical cancer screening in women infected with the human immunodeficiency virus.
Goldie SJ; Freedberg KA; Weinstein MC; Wright TC; Kuntz KM
Am J Med; 2001 Aug; 111(2):140-9. PubMed ID: 11498068
[TBL] [Abstract][Full Text] [Related]
12. Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses.
Arbyn M; Sasieni P; Meijer CJ; Clavel C; Koliopoulos G; Dillner J
Vaccine; 2006 Aug; 24 Suppl 3():S3/78-89. PubMed ID: 16950021
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of p16/Ki-67 Dual-Stained Cytology Reflex Following Co-testing with hrHPV Genotyping for Cervical Cancer Screening.
Harper DM; Anderson RJ; Baker E; Yu TM
Cancer Prev Res (Phila); 2023 Jul; 16(7):393-404. PubMed ID: 37210751
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: the FASE study.
Monsonego J; Hudgens MG; Zerat L; Zerat JC; Syrjänen K; Halfon P; Ruiz F; Smith JS
Int J Cancer; 2011 Aug; 129(3):691-701. PubMed ID: 20941740
[TBL] [Abstract][Full Text] [Related]
15. Human papillomavirus testing for triage of women with low-grade squamous intraepithelial lesions.
Cuzick J; Thomas Cox J; Zhang G; Einstein MH; Stoler M; Trupin S; Behrens CM
Int J Cancer; 2013 Feb; 132(4):959-66. PubMed ID: 22806936
[TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness of human papillomavirus-16/18 genotyping in cervical cancer screening.
Huh WK; Williams E; Huang J; Bramley T; Poulios N
Appl Health Econ Health Policy; 2015 Feb; 13(1):95-107. PubMed ID: 25385310
[TBL] [Abstract][Full Text] [Related]
17. The cost-effectiveness of human papillomavirus screening for cervical cancer. A review of recent modelling studies.
Holmes J; Hemmett L; Garfield S
Eur J Health Econ; 2005 Mar; 6(1):30-7. PubMed ID: 15682286
[TBL] [Abstract][Full Text] [Related]
18. Efficiency of the APTIMA HPV Assay for detection of HPV RNA and DNA targets.
Getman D; Aiyer A; Dockter J; Giachetti C; Zhang F; Ginocchio CC
J Clin Virol; 2009 Jul; 45 Suppl 1():S49-54. PubMed ID: 19651369
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more.
Goldie SJ; Kim JJ; Wright TC
Obstet Gynecol; 2004 Apr; 103(4):619-31. PubMed ID: 15051550
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of high-risk HPV DNA testing for cervical cancer screening in South Africa.
Vijayaraghavan A; Efrusy M; Lindeque G; Dreyer G; Santas C
Gynecol Oncol; 2009 Feb; 112(2):377-83. PubMed ID: 19081611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
